3 Prominent Stocks Estimated To Be Trading At Least 14.6% Below Intrinsic Value
AbbVie Inc ABBV
$215.40
▲ +1.07%
(+$2.28)
Index member:
S&P 500
Open
$213.12
Prev Close
$213.12
Day Range
$211.36 – $215.94
52W Range
$181.73 – $244.81
Market Cap
$380.57B
P/E (TTM)
104.60
Beta
0.30
Div Yield
3.21%
EPS (TTM)
$2.05
📋 Company Profile
| Industry | Biotechnology |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2013-01-02 |
| Shares Out. | 1,766,790,000 |
| Website | abbvie.com/ ↗ |
| Phone | 13023513367 |
AbbVie Inc is a publicly traded company under the ticker symbol ABBV on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
40 analysts (2026-05-01)
📰 Latest News for ABBV
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug
Discover 3 Stocks That May Be Trading Below Their Estimated Value
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
FDA Approves Pivekimab Sunirine-pvzy For Blastic Plasmacytoid Dendritic Cell Neoplasm, An Ultra-Rare Hematologic Malignancy
Dividend Income Update Q1 2026
Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress